Altimmune, Inc.

NasdaqGM:ALT 株式レポート

時価総額:US$545.8m

Altimmune マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Vipin Garg

最高経営責任者

US$5.5m

報酬総額

CEO給与比率11.3%
CEO在任期間6yrs
CEOの所有権0.4%
経営陣の平均在職期間5.3yrs
取締役会の平均在任期間5.3yrs

経営陣の近況

Recent updates

Regulatory And Clinical Catalysts Ahead For Altimmune

Oct 28

Consider Buying Potential Takeover Target Altimmune

Oct 02

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Sep 21

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Sep 12
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Aug 27

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27
We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

Sep 17
Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

CEO報酬分析

Altimmune の収益と比較して、Vipin Garg の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$5mUS$620k

-US$88m

Sep 30 2023n/an/a

-US$78m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$85m

Dec 31 2022US$3mUS$580k

-US$85m

Sep 30 2022n/an/a

-US$87m

Jun 30 2022n/an/a

-US$97m

Mar 31 2022n/an/a

-US$102m

Dec 31 2021US$3mUS$566k

-US$97m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$1mUS$514k

-US$49m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$815kUS$500k

-US$21m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$34m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$2mUS$44k

-US$42m

報酬と市場: Vipinの 総報酬 ($USD 5.48M ) は、 US市場 ($USD 2.34M ) の同規模の企業の平均を上回っています。

報酬と収益: Vipinの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Vipin Garg (66 yo)

6yrs

在職期間

US$5,482,089

報酬

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Vipin Garg
President6yrsUS$5.48m0.41%
$ 2.2m
Matthew Harris
Chief Medical Officer5.3yrsUS$2.24m0.078%
$ 423.3k
Raymond Jordt
Chief Business Officer1.8yrsUS$2.94m0.021%
$ 112.6k
Andrew Shutterly
Acting CFO1.8yrsデータなし0.016%
$ 87.3k
Bertrand Georges
Chief Technology Officer7.5yrsデータなしデータなし
M. Roberts
Chief Scientific Officer11.9yrsUS$1.41m0.061%
$ 332.7k
Tony Blandin
Vice President of Quality & Compliance Management2.8yrsデータなしデータなし

5.3yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: ALTの経営陣は経験豊富で経験豊富です(平均在職期間は5.3年)。


取締役

名称ポジション在職期間報酬所有権
Vipin Garg
President6yrsUS$5.48m0.41%
$ 2.2m
Mitchel Sayare
Independent Chairman14.6yrsUS$119.68k0.037%
$ 202.4k
John Gill
Independent Director20.3yrsUS$103.68k0.0039%
$ 21.3k
Philip Hodges
Independent Director7.5yrsUS$115.68k0.012%
$ 67.0k
Klaus Schafer
Independent Director7.5yrsUS$104.68k0.013%
$ 70.5k
Catherine Sohn
Independent Director1.7yrsUS$273.47k0%
$ 0
Wayne Pisano
Independent Director6.3yrsUS$108.68k0.012%
$ 65.3k
Caroline Apovian
Member of Obesity Scientific Advisory Board2.3yrsデータなしデータなし
Diane Jorkasky
Independent Director4.5yrsUS$95.68k0%
$ 0
Rohit Loomba
Member of Mash Scientific Advisory Board2.3yrsデータなしデータなし
Mazen Noureddin
Member of Mash Scientific Advisory Board2.3yrsデータなしデータなし
Naga Chalasani
Member of Mash Scientific Advisory Board2.3yrsデータなしデータなし

5.3yrs

平均在職期間

71.5yo

平均年齢

経験豊富なボード: ALTの 取締役会経験豊富 であると考えられます ( 5.3年の平均在任期間)。